Blackstone Group

The Blackstone Group is an investment firm headquartered in New York, with offices in Abu Dhabi, Beijing, Copenhagen, Dubai, Dublin, Dusseldorf, Frankfurt, Hong Kong, Houston, London, Los Angeles, Luxembourg, Madrid, Mumbai, Pari, San Francisco, Sao Paulo, Seoul, Shanghai, Singapore, Sydney, and Tokyo. Blackstone’s alternative asset management businesses include private equity, real estate, hedge funds, credit, and secondary funds. The firm’s private equity vehicles typically carry out leveraged buyout acquisitions of seasoned companies, transactions involving growth equity or start-up businesses in established industries, minority investments, corporate partnerships, distressed debt, structured securities, and industry consolidations in a wide variety of industries and geographies. Blackstone also provides various financial advisory services including corporate, mergers and acquisitions, restructuring, reorganization, and fund placement advisory. In March 2008, Blackstone acquired GSO Capital Partners, a credit-oriented alternative asset manager, which manages CLOs, senior debt funds, multi-strategy credit funds, distressed debt, and mezzanine funds focused on the leveraged finance marketplace. Please see GSO Capital Partner's profile for further details. The Blackstone Group was approved by the Shanghai Government in Q2 2011 for the Qualified Foreign Limited Partner pilot program, which would allow foreign investors to convert a pre-approved amount of dollars to local currency to make domestic investments. In 2011, Blackstone formed the Tactical Opportunities business; a proprietary investment strategy that pursues a global multi-asset class approach to investing in illiquid assets focused on timely opportunities that fall outside other Blackstone alternative fund strategies. In April 2013, Blackstone made plans to acquire Credit Suisse's secondary private equity business, Strategic Partners. The deal was finalized in August 2013. In 2018, Blackstone acquired Clarus Ventures, which made investments in medical and life science companies; the firm became Blackstone Life Sciences. In July 2019, Blackstone completed its conversion to a corporation from a publicly traded partnership.Read more ⏷